Drug Design, Development and Therapy (Jul 2021)
Mechanism of Tetrandrine Against Endometrial Cancer Based on Network Pharmacology
Abstract
Wenqian Shang,1 Jing Zhang,2 Haibo Song,2 Shunfei Zhu,3 Aimin Zhang,1 Yushuang Hua,1 Shujun Han,4 Yan Fu5 1Department of Traditional Chinese Medicine, Zibo Maternal and Child Health Hospital, Zibo, Shandong, 255000, People’s Republic of China; 2Translational Medicine Center, Zibo Maternal and Child Health Hospital, Zibo, Shandong, 255000, People’s Republic of China; 3Clinical Laboratory, Zibo Maternal and Child Health Hospital, Zibo, Shandong, 255000, People’s Republic of China; 4Surgical Department, Zhangdian District Hospital of Traditional Chinese Medicine, Zibo, 255000, Shandong, People’s Republic of China; 5Shandong University of Technology, Zibo, 255000, Shandong, People’s Republic of ChinaCorrespondence: Aimin Zhang; Wenqian ShangDepartment of Traditional Chinese Medicine, Zibo Maternal and Child Health Hospital, No. 66 North Tianjin Road, Zhangdian District, Zibo, Shandong, People’s Republic of ChinaTel +86 18505330408; +86 15053358995Email [email protected]; [email protected]: Endometrial cancer (EC) is one of the most common gynaecological malignancies, and its incidence has been rising over the past decade. Tetrandrine, a bisbenzylisoquinoline alkaloid, has been isolated from a vine used in traditional Chinese medicine, Stephania tetrandra. However, the key mechanism of tetrandrine in EC is still unclear.Purpose: This research was designed to predict the molecular mechanisms of tetrandrine against EC based on network pharmacology and to further verify these predictions by in vitro experiments.Methods: The potential therapeutic targets of tetrandrine against EC were predicted by using public databases. Afterwards, the protein–protein interaction (PPI) network of the common targets was constructed, and the key gene targets were obtained. Biological function and pathway enrichment analyses were performed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Furthermore, molecular docking and in vitro experiments were carried out to verify the predictions. The cell counting kit‑8 (CCK‑8) assay, Hoechst 33258 staining, flow cytometry analysis, qRT-PCR, Western blot analysis and an immunofluorescence assay were performed.Results: Our findings identified 111 potential therapeutic targets of tetrandrine against EC. We obtained 7 key gene targets from the PPI network analysis. Furthermore, GO enrichment analysis indicated that these targets were mainly associated with metabolic processes, responses to stimulus, and biological regulation. The KEGG pathway analysis showed that the common targets were mainly distributed in the PI3K/Akt signalling pathway. A potential interaction of tetrandrine with Akt1 was revealed by molecular docking. In addition, in vitro experiments showed that tetrandrine significantly inhibited cell proliferation and induced apoptosis in Ishikawa and HEC-1-B cells in dose- and time-dependent manners. The results also revealed that tetrandrine can downregulate the expression of Bcl-2 and upregulate the expression of Bax at the mRNA level. The mRNA levels of Akt were not significantly different in the various tetrandrine (0, 10 and 20μM) groups. However, Western blot analysis demonstrated that the protein expression ratios of p-Akt/Akt decreased at the protein level. The results were further confirmed by immunofluorescence assays.Conclusion: Based on bioinformatic analysis and experimental verification, our findings demonstrated that tetrandrine exerted tumour-suppressive effects on EC by regulating the PI3K/Akt signalling pathway.Keywords: endometrial carcinoma, mechanism, network pharmacology, tetrandrine
